Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00008398 · ClinicalTrials.gov registry record · Phase 3
Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00008398 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group.
The verdict
NCT00008398, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Sargramostim may lessen symptoms of mucositis in patients receiving radiation therapy for head and neck cancer. It is not yet known if sargramostim is more effective than no treatment in reducing mucositis caused by radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of sargramostim in decreasing mucositis in patients who are receiving radiation therapy for head and neck cancer.
Interventions
- PROCEDURE quality-of-life assessment
- RADIATION radiation therapy
- BIOLOGICAL sargramostim
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00008398
The ClinicalTrials.gov registry entry for NCT00008398 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which quality-of-life assessment is the first listed.
NCT00008398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00008398 about?
NCT00008398 is a clinical study titled "Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer". RATIONALE: Sargramostim may lessen symptoms of mucositis in patients receiving radiation therapy for head and neck cancer. It is not yet known if sargramostim is more effective than no treatment in reducing mucositis caused by radiation therapy. PURPOSE: Randomized phase III trial to determine the ...
What is the current status of trial NCT00008398?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-10.
What interventions are being tested in trial NCT00008398?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), radiation therapy (RADIATION), sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00008398?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.